Skip to main content
TipRanks
Go Ultimate75% OFF

Immunovant (IMVT) AI Stock Analysis

963 Followers
IMVT

Immunovant

(NASDAQ:IMVT)

Select Model
Rating:53Neutral
Price Target:$31.00▼(-4.67% Downside)
Action:reiterated
Date:11/10/26

The score is held back primarily by weak financial performance (very large losses and heavy cash burn with minimal revenue), partially offset by a debt-free balance sheet. The earnings call provided a meaningful boost due to strong launch/pipeline momentum and positive sentiment, while technical signals are mixed and valuation remains constrained by ongoing unprofitability and no dividend.

Positive Factors
LISRAYA launch demandThe rapid commercial uptake demonstrates meaningful patient and physician demand soon after approval, while broad prescribing and early payer access support scalability. This gives Immunovant a developing commercial base that can fund future growth as adoption expands.
Negative Factors
Large persistent lossesRevenue remains very small relative to operating expenses, leaving the company far from self-funded profitability. Expanding losses indicate that development and commercial investments have not yet translated into sufficient revenue, increasing dependence on existing capital and future financing.

Immunovant (IMVT) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%IMVT+39.45%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.73B
Dividend Yield
―
Average Volume (3M)
1.42M
Price to Earnings (P/E)
-12.7
Beta (1Y)
1.24
Revenue Growth
―
EPS Growth
9.82%
Country
US
Employees
315
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Immunovant Business Overview & Revenue Model

Company Description

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fu...

Immunovant Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q2-2027)|% Change Since:6.52%|Next Earnings Date:Feb 16, 2027
Earnings Call SentimentPositive

The call was strongly positive, driven by the successful LISRAYA launch, robust early commercial demand, positive 1402 RA maintenance data, favorable NIU results, and compelling mosliciguat PH-ILD data. The company also has substantial cash, active share repurchases, and a broad 2027 pipeline. The main negative items were the failed CLE study, the likely discontinuation of Sjögren's development, ongoing uncertainty around the 1402 regulatory path, a potential modest near-term inventory headwind, and the quarterly net loss. Highlights significantly outweighed lowlights.

Positive Updates

LISRAYA Commercial Launch Shows Strong Initial Demand
LISRAYA was approved in August and generated $31 million of net revenue during approximately five weeks on the market through September 30. Hundreds of patients were on paid drug at quarter-end, many hundreds were on paid drug by the call, and the company reported a broad initial prescriber base, strong patient and physician enthusiasm, and good early payer uptake.

Negative Updates

CLE Study Did Not Succeed
The company announced earlier in the quarter that it had not succeeded in the CLE study.

Company Guidance

For LISRAYA, management expects “a modest headwind” from inventory dynamics in the December quarter and expects inventory and stocking to be “completely irrelevant as we round the corner into next year”; for IMVT-1402, it expects to update trial plans “probably later this year or early next year” after FDA discussions. In 2027, Roivant expects to file the sNDA for NIU, report top-line data for 1402 in Graves’ and data in MG, and pursue “multiple program indication expansion,” while for mosliciguat it expects updates “in the coming months” on initiation of other trials, with a “pretty broad program” under consideration across PAH, IPF, PPF, and other forms of pulmonary hypertension, although it cannot commit to specific indications or whether they will be phase IIs or phase IIIs. It also expects to provide an update “relatively soon” on Graves’ timing and enrollment.

Immunovant Financial Statement Overview

Summary

Overall financials are weak: minimal TTM revenue (~$7.1M) with no growth, extremely large operating losses (TTM EBIT about -$531M) and deep net losses (TTM net income about -$509M), alongside heavy ongoing cash burn (TTM operating cash flow and free cash flow about -$395M). The key offset is a relatively strong balance sheet with no debt and still-meaningful equity (~$657M), but continued losses and cash outflows remain the dominant risk.

Income Statement

12Very Negative

Balance Sheet

63Positive

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue7.09M00000
Gross Profit6.99M00000
EBITDA-509.88M-504.98M-412.57M-258.54M-198.28M-156.69M
Net Income-508.96M-505.61M-413.84M-259.34M-210.96M-156.73M
Balance Sheet
Total Assets760.97M957.01M776.22M666.71M405.84M515.56M
Cash, Cash Equivalents and Short-Term Investments722.27M902.11M713.97M635.37M376.53M493.82M
Total Debt072.00K98.00K138.00K1.22M2.36M
Total Liabilities104.02M104.42M68.78M48.95M43.34M45.74M
Stockholders Equity656.95M852.59M707.45M617.76M362.49M469.82M
Cash Flow
Free Cash Flow-395.01M-407.32M-376.63M-214.59M-188.39M-106.37M
Operating Cash Flow-395.00M-407.31M-375.87M-214.23M-188.19M-106.11M
Investing Cash Flow-8,000-8,000-759.00K-360.00K-197.00K-254.00K
Financing Cash Flow596.22M595.76M454.49M472.43M70.89M200.13M

Immunovant Technical Analysis

Technical Analysis SentimentPositive
Last Price32.52

Price Trends

50DMA32.28Positive
100DMA36.37Negative
200DMA32.46Positive

Market Momentum

MACD0.76Negative
RSI54.18Neutral
STOCH53.48Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMVT, the sentiment is Positive. The current price of 32.52 is above the 20-day moving average (MA) of 31.29, above the 50-day MA of 32.28, and above the 200-day MA of 32.46, indicating a bullish trend. The MACD of 0.76 indicates Negative momentum. The RSI at 54.18 is Neutral, neither overbought nor oversold. The STOCH value of 53.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMVT.

Immunovant Risk Analysis

Immunovant disclosed 77 risk factors in its most recent earnings report. Immunovant reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Legislation targeting biotechnology companies with ties to certain foreign adversaries, including the BIOSECURE Act, could materially adversely affect our business, supply chain and results of operations.Q1, 2026
2.The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities.Q1, 2026
3.We may not be able to attract or retain qualified management, scientific, clinical and commercial personnel due to the intense competition for qualified individuals among biotechnology, pharmaceutical and other businesses.Q1, 2026

Immunovant Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IMVT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AUPHAUPH84Outperform$2.00B6.2851.92%―21.04%312.89%
PTGXPTGX72Outperform$8.09B24.0442.83%―163.69%574.89%
TGTXTGTX72Outperform$9.81B87.1017.62%―68.78%-75.71%
KYMRKYMR60Neutral$10.19B-32.89-22.39%―133.77%-0.64%
VRDNVRDN55Neutral$3.57B-8.12-69.76%―-62.83%-18.22%
IMVTIMVT53Neutral$6.73B-12.70-63.01%――9.82%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%IMVTTGTXVRDNAUPHPTGXKYMRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IMVT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IMVTImmunovant, Inc.32.529.9343.96%
TGTXTG Therapeutics64.8832.93103.07%
VRDNViridian Therapeutics, Inc.31.441.103.63%
AUPHAurinia Pharmaceuticals14.89-0.79-5.04%
PTGXProtagonist Therapeutics Inc124.0238.6245.22%
KYMRKymera Therapeutics, Inc.119.3953.3580.78%

Immunovant Corporate Events

Executive/Board ChangesShareholder Meetings

Immunovant Shareholders Back Board, Auditor and Executive Pay

Positive
Sep 3, 2026

On September 2, 2026, Immunovant, Inc. held its 2026 Annual Meeting of Stockholders, with approximately 96% of eligible common and Series A preferred shares represented, reflecting strong shareholder engagement. At the meeting, stockholders elected J...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026